Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-9966

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines ; volume:36 ; number:1 ; day:4 ; month:12 ; year:2017 ; pages:1-12 ; date:12.2017
Journal of experimental & clinical cancer research ; 36, Heft 1 (4.12.2017), 1-12, 12.2017

Keyword: Krebs
Onkologie

Creator: La Monica, Silvia

Contributor: Cretella, Daniele
Bonelli, Mara
Fumarola, Claudia
Cavazzoni, Andrea
Digiacomo, Graziana
Flammini, Lisa
Barocelli, Elisabetta
Minari, Roberta
Naldi, Nadia
Petronini, Pier Giorgio
Tiseo, Marcello
Alfieri, Roberta
SpringerLink (Online service)

DOI: 10.1186/s13046-017-0653-7

URN: urn:nbn:de:1111-201802038465

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:48 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

La Monica, Silvia
Cretella, Daniele
Bonelli, Mara
Fumarola, Claudia
Cavazzoni, Andrea
Digiacomo, Graziana
Flammini, Lisa
Barocelli, Elisabetta
Minari, Roberta
Naldi, Nadia
Petronini, Pier Giorgio
Tiseo, Marcello
Alfieri, Roberta
SpringerLink (Online service)

Other Objects (12)

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma

An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer

Related objects

Reset password